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Abstract
Background: Lung cancer is the most common cause of cancer-related deaths worldwide. The aim of this study was to
investigate the association of five extensively-studied polymorphisms in PTGS2 (rs689466, rs5275, rs20417) and CYP2E1
(rs2031920, rs6413432) genes with lung cancer risk in a large northeastern Chinese population.
Methodology/Principal Findings: This is a hospital-based case-control study involving 684 patients with lung cancer and
604 cancer-free controls. Genotyping was performed using the PCR-LDR method. Data were analyzed using Haplo.stats and
MDR programs. There were significant differences between patients and controls in allele/genotype distributions of rs5275
(P= 0.002/0.003) and rs6413432 (P= 0.037/0.044), as well as in genotype distributions of rs689466 (P= 0.02). The risk for lung
cancer associated with the rs5275-C mutant allele was decreased by 60% (95% CI [confidence interval]: 0.21–0.74; P= 0.004)
under the recessive model. Carriers of rs689466-G mutant allele had a 28% (95% CI: 0.57–0.92; P= 0.008) reduced risk of
developing lung cancer relative to the AA genotype carriers. In haplotype analysis, haplotype G-C-C-T (in order of rs689466,
rs5275, rs2031920 and rs6413432) decreased the odds of lung cancer by 28% (95% CI: 0.51–0.93; P= 0.019) after adjusting
for confounding factors, whereas haplotype A-T-T-T had 1.49-fold (95% CI: 1.21–1.79; P= 0.012) increased risk for lung
cancer. Using MDR method, the overall best model including rs5275, rs689466 and rs6413432 polymorphisms was identified
with a maximal testing accuracy of 66.1% and a maximal cross-validation consistency of 10 out of 10 (P= 0.003).
Conclusions/Significance: Our findings demonstrated a potentially synergistic association of PTGS2 and CYP2E1
polymorphisms with the underlying cause of lung cancer in northeastern Chinese.
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Introduction
Lung cancer is the most common cause of cancer-related deaths
worldwide. The reduction of tobacco consumption is currently the
major strategy to reduce lung cancer burden. However, identifi-
cation of genes involved in causing the disease could contribute to
discovering the underlying mechanisms and lead to a compre-
hensive prevention strategy as well as targeted therapy [1]. Some
individuals are more susceptible to lung cancer than others and
knowledge for the explanation for this inter-individual divergence
in susceptibility is important for the purpose of developing
methods that can predict the risk [2]. Although common genetic
variants involved in lung cancer have been identified by genome-
wide association studies, detailed information about the genetic
factors remains to be elucidated. It seems that rarer genetic
variants are likely to account for most of the individual
susceptibility [1]. The candidate gene approach, which deals with
previously identified genes that are thought to participate in the
pathophysiology of the disease, is still employed as a useful tool.
In this study prostaglandin-endoperoxide synthase 2 (PTGS2)
and cytochrome P450, family 2, subfamily E, polypeptide 1
(CYP2E1) were selected as candidate genes susceptible to lung
cancer based on their critical involvement in the mechanism of
lung carcinogenesis [3,4]. PTGS2 is a highly inducible gene,
activated by cytokines, growth factors, oncogenes and chemical
carcinogens [5]. Functional studies suggest that PTGS2 plays a
role in carcinogenesis and is overexpressed in many human
malignancies [6,7], especially in lung adenocarcinoma and
squamous cell carcinoma [8,9]. CYP2E1 is an ethanol- and
drug-metabolizing enzyme that can activate procarcinogens and
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hepatotoxicants, and generate reactive oxygen species [10,11]. In
addition, CYP2E1 can activate human carcinogens, including
benzene and N-nitrosamines found in cigarette smoke [12,13].
Due to these important functions, PTGS2 and CYP2E1 genes
were investigated as logical candidates for lung cancer suscepti-
bility.
Many studies have evaluated the association of polymorphisms
in PTGS2 and CYP2E1 genes with lung cancer; however, the
results have been inconsistent, and the biological effects based on
statistical reasoning are still elusive. Given the importance of
ethnic divergences in the genetic effects on complex diseases and
the fact that genetic markers for proposed gene-disease associa-
tions vary in frequency across the populations, we evaluated five
extensively studied polymorphisms in PTGS2 (rs689466, rs5275,
rs20417) and CYP2E1 (rs2031920, rs6413432) genes in a large
northeastern Chinese population to examine their associations,
both individually and in combination, with lung cancer risk.
Methods
Study population
This was a hospital-based case-control study involving a total of
1286 subjects from the northeastern of China (Harbin city,
Heilongjiang province). All subjects were local residents of Han
descent. There were study population included 684 patients
clinically diagnosed as lung cancer and 602 age-matched cancer-
free controls. The study was approved by the Ethics Committee of
Harbin Medical University, and conducted according to the
Declaration of Helsinki Principles. All subjects signed the written
informed consent.
Diagnostic criteria and demographic characteristics
Lung cancer was diagnosed by chest radiograph and either high
resolution computed tomography (CT) or enhanced CT or PET-
CT scan and was pathologically confirmed by biopsy. Clinical
subtypes of lung cancer consisted of squamous cell cancer,
adenocarcinoma, small cell cancer and unspecified lung cancer.
Age and gender were recorded when the subjects were recruited.
Body weight in kilograms and height in meters were measured to
calculate the body mass index (BMI, kg/m2). The status of
cigarette smoking and alcohol drinking was defined at the time of
the survey. Smoking was categorized as never, ever or current
smoking (at least one cigarette per day). Drinking was categorized
as never, ever or current drinking. Here, current drinking referred
to consumption of at least one alcoholic drink during the past 30
days.
Genotyping
Blood samples (2 mL) were collected and genomic DNA was
extracted from white blood cells using the TIANamp Blood DNA
Kit (Tiangen Biotect [Beijing] Co., LTD). Genotyping was
conducted using the PCR-LDR (ligase detection reactions) method
by ABI 9600 system (Applied Biosystems, USA) [14]. Cycling
parameters were as the following: 94uC for 2 min; 35 cycles of
94uC for 15 s; 60uC for 15 s; 72uC for 30 s; and a final extension
step at 72uC for 5 min. For each polymorphism, two specific
probes to discriminate the specific bases and one common probe
were synthesized. The common probe was labeled at the 39 end
with 6-carboxy-fluorescein and phosphorylated at the 59 end. The
reacting conditions of LDR were: 94uC for 2 min, 20 cycles of
94uC for 30 s and 60uC for 3 min. After reaction, 1 mL LDR
reaction products were mixed with 1 mL ROX passive reference
and 1 mL loading buffer, and then denatured at 95uC for 3 min,
and chilled rapidly in ice water. The fluorescent products of LDR
were differentiated using ABI sequencer 377 (Applied Biosystems,
USA).
Statistical analysis
Comparisons between lung cancer patients and controls were
conducted by unpaired t-test for continuous variables and by x2
test for categorical variables. To avoid gross genotyping error, all
polymorphisms were checked for consistency with Hardy-Wein-
berg equilibrium on a contingency table of observed-versus-
predicted genotype frequencies by using Pearson x2 test or Fisher’s
exact test. Genotypes were compared by Logistic regression
analysis under assumptions of additive, dominant and recessive
models of inheritance, respectively. Statistical significance was
defined as P,0.05.
Haplotype frequencies were estimated by using the haplo.em
program, and odds ratio (ORs) and 95% confidence interval (CI)
were estimated by haplo.cc and haplo.glm programs according to
a generalized linear model [15]. Furthermore, the haplo.score was
used to model an individual’s phenotype as a function of each
inferred haplotype, which was weighted by their estimated
probability to account for haplotype ambiguity. The haplo.em,
haplo.glm, and haplo.score were implemented using Haplo.stats
software (version 1.4.0) developed by the R language (http://www.
r-project.org/). Study power was calculated using PS (Power and
Sample Size Calculations) software (version 3.0).
Interaction analysis was conducted in the open-source MDR
software (version 2.0) (www.epistasis.org) [16,17]. All possible
combinations of one to four polymorphisms were constructed
using MDR constructive induction. Then a Bayes classifier in the
context of 10-fold cross-validation was employed to estimate the
testing accuracy of each best model. A single best model had
maximal testing accuracy and cross-validation consistency, which
measures the number of times of 10 divisions of the data that the
best model was found. Statistical significance was evaluated using a
1000-fold permutation test to compare observed testing accuracies
with those expected under the null hypothesis of null association.
Permutation testing corrects for multiple testing by repeating the
entire analysis on 1000 datasets that are consistent with the null
hypothesis.
Results
Baseline characteristics
The demographics and risk factors in the study population are
summarized in Table 1. Cases and controls were well matched by
age. Male gender, smoking, drinking and higher BMI level were
associated with increased risk for lung cancer. Among all lung
cancer patients, the subtype of adenocarcinoma, squamous cell
cancer, small cell cancer, and unspecified cancer accounted for
37.54%, 32.26%, 20.83%, and 9.38%, respectively.
Single-locus analysis
With regard to rs20417, the frequency of mutated homozygote
was zero in this study population, although its minor allele
frequency was estimated at 7% in Beijing Han Chinese, and 41%
in Nigerians (HapMap database). The genotype distributions of
the other four polymorphisms followed Hardy-Weinberg equilib-
rium in control groups (P.0.05). As shown in Table 2, significant
difference between lung cancer patients and controls was observed
in allele and genotype distributions of rs5275 (Pallele = 0.002 and
Pgenotype = 0.003) and rs6413432 (Pallele = 0.037 and Pgeno-
type = 0.044), and in genotype distributions of rs689466
(P= 0.02). Based on power calculation, the present study of 684
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patients and 602 controls had 83.8% power to detect a significant
association for rs5275.
Notably, for rs5275, the risk associated with mutant allele or
genotype was decreased by 27% (95% CI: 0.6–0.9; P=0.002)
under the additive model, by 25% (95% CI: 0.59–0.95; P=0.017)
under the dominant model, and by 60% (95% CI: 0.21–0.74;
P=0.004) under the recessive model. With regard to rs689466,
carriers of the mutant G allele had a 28% reduced risk of
developing lung cancer (95% CI: 0.57–0.92; P=0.008) compared
with the AA carriers (Table 2). A significant difference was
identified for rs6413432 in association with lung cancer under the
additive (OR=0.82; 95% CI: 0.68–0.99; P=0.042) and dominant
(OR=0.75; 95% CI: 0.6–0.95; P=0.016) models. No significant
association was detected for rs2031920 under the three genetic
models.
Genotype-phenotype analysis
In view of the differences in anthropometric characteristics
between lung cancer patients and controls, it was of interest to
investigate their correlation with the studied polymorphisms. We
observed significant association between rs5275 and gender
(x2 = 6.07; P=0.048), as well as a borderline association of
rs5275 with smoking (x2 = 5.16; P=0.066). No significant
association of other polymorphisms with anthropometric charac-
teristics was observed (data not shown).
Haplotype analysis
Haplotype frequencies of the four polymorphisms examined
were estimated and compared between cases and controls
(Table 3). The frequency of haplotype A-T-T-T (in order of
rs689466, rs5275, rs2031920 and rs6413432) was significantly
higher (P=0.02) in patients than that in controls after statistical
correction, whereas the frequency of haplotype G-C-C-T was
significantly lower (P=0.034) in patients. After assigning the
commonest haplotype A-T-C-T as the reference, haplotype G-C-
C-T decreased the odds of lung cancer by 28% (95% CI: 0.51–
0.93; P=0.019, study power= 97.7%) after adjusting for age,
gender, smoking and drinking. In contrast, haplotype A-T-T-T
had a 1.49-fold (95% CI: 1.21–1.79; P=0.012, study power:
82.1%) increased risk.
Table 1. The baseline characteristics of study population.
Characteristics
Patients
(N=684)
Controls
(N=602) P*
Age (years), mean 6 SD 57.2469.84 56.8069.95 0.776
Gender (male) (%) 72.78 66.49 0.013
BMI (kg/m2), mean 6 SD 22.963.25 21.8762.57 0.032
Smoking (%) ,0.005
Current 28.22 6.99
Ever 8.04 0.54
Never 63.74 92.47
Drinking (%) ,0.005
Current 15.23 5.38
Ever 1.61 2.69
Never 83.16 91.94
Lung cancer type (%)
Squamous cell cancer 32.26 NA
Adenocarcinoma 37.54 NA
Small cell cancer 20.83 NA
Unspecified 9.38 NA
Abbreviations: BMI, body mass index; NA, not available.
*P values were calculated by using unpaired t-test for age and BMI, and by x2
test for categorical variables.
doi:10.1371/journal.pone.0039814.t001
Table 2. The genotype distributions and allele frequencies of the studied polymorphisms between patients and controls, and their
risk predictions for lung cancer under three genetic models of inheritance.
Polymorphism
Patients
(N=684)
Controls
(N=602) Px2 Genetic models OR; 95% CI; P
rs689466 AA 230 161 Additive 0.87; 0.74–1.01; 0.07
AG 318 320 0.02 Dominant 0.72; 0.57–0.92; 0.008
GG 136 121 Recessive 0.99; 0.75–1.3; 0.923
G (%) 43.13 46.68 0.071 Study power: 43.9%
rs5275 TT 486 389 Additive 0.73; 0.6–0.9; 0.002
TC 185 181 0.003 Dominant 0.75; 0.59–0.95; 0.017
CC 15 32 Recessive 0.4; 0.21–0.74; 0.004
C (%) 15.72 20.35 0.002 Study power: 83.8%
rs2031920 CC 403 361 Additive 1.02; 0.84–1.23; 0.855
CT 250 211 0.82 Dominant 1.04; 0.84–1.31; 0.702
TT 31 30 Recessive 0.91; 0.54–1.51; 0.704
T (%) 22.81 22.51 0.857 Study power: 5.4%
rs6413432 TT 472 377 Additive 0.82; 0.68–0.99; 0.042
TA 182 198 0.044 Dominant 0.75; 0.6–0.95; 0.016
AA 30 27 Recessive 0.98; 0.57–1.66; 0.931
A (%) 17.69 20.93 0.037 Study power: 54.8%
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0039814.t002
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Interaction analysis
An exhaustive MDR analysis that evaluated all possible
combinations of four studied polymorphisms is summarized in
Table 4. Each best model was accompanied with its testing
accuracy, cross-validation consistency and significant level as
determined by permutation testing. The overall best MDR model
included rs5275, rs689466, and rs6413432 polymorphisms. This
model had a maximal testing accuracy of 66.1% and a maximal
cross-validation consistency of 10 out of 10. This model was
significant at the 0.003 level, indicating that a model this good or
better was observed only by three times out of 1000 permutations
and was thus unlikely under the null hypothesis of null association.
Discussion
In this study we found significant associations of PTGS2 and
CYP2E1 polymorphisms with the susceptibility to lung cancer in
northeastern Chinese. Moreover, as implicated by haplotype and
interaction analyses, we found potentially synergistic effect
between these two genes, which reinforces single-locus results
and contributes to strong susceptibility to lung cancer. To our
knowledge, this is the first case-control study investigating the joint
effect of PTGS2 and CYP2E1 genes on lung cancer.
Although the candidate gene approach cannot replace the
genome-wide association study in unraveling the genetics of
complex traits, it remains an important alternative strategy,
particularly in the context of adequate sample sizes, ethnic
homogeneous populations, and solid biological evidence of the
genes concerned. To generate robust data, it has been proposed
that a large sample size involving .1000 subjects in each group is
required [18]. Despite that only 684 patients and 602 controls
were enrolled in this study, in view of wide divergence in genetic
distributions, a priori power calculation indicated that this study
had .80% power to detect the loci of realistic effect size.
Moreover, our study subjects were ethnically homogeneous and
local residents of Harbin city, a site where the prevalence of lung
cancer is relatively high likely because of the indoor air pollution
from the unventilated coal-fueled stoves [19]. In addition,
genotypes of studied polymorphisms were in Hardy-Weinberg
equilibrium in controls, suggesting the results are unlikely to be
biased by genotyping errors or population stratification. Further-
more, selection of genes and polymorphisms was based on strong
biological, genetic and epidemiological indications [20–23].
However, considering the complexity of lung cancer, our
preliminary results should be considered as hypothesis needing
to be tested in larger well-designed studies.
Recently, several global meta-analyses have summarized the
individual findings on PTGS2 and CYP2E1 genes and confirmed
the significantly protective effect of rs5275, rs2031920 and
rs6413432 mutant alleles on lung cancer [4,24,25]. In the current
study, we identified that carriers of mutant alleles of rs689466,
rs5275 and rs2031920 were at remarkably reduced risk for lung
cancer. To expand the findings, we reported a potential synergism
between PTGS2 and CYP2E1 genes on lung cancer risk, as
reflected by haplotype and interaction analyses. Despite the
marginal association of rs6413432 in single-locus analysis,
compared with haplotype A-T-T-A (in order of rs689466,
rs5275, rs2031920 and rs6413432), the risk magnitude associated
with haplotype A-T-T-T was remarkably augmented and was
independent of traditional risk factors, demonstrating a contribu-
tion of rs6413432-T allele to lung cancer susceptibility. However,
in the presence of rs689466-G and rs5275-C alleles, the risk-
conferring role of rs6413432-T allele was markedly attenuated
showing a 28% reduced risk for haplotype G-C-C-T. Using the
MDR method, which is nonparametric and genetically model-free
in design [26], we constructed the overall best model encompass-
ing polymorphisms rs5275, rs689466, and rs6413432 with strong
synergistic effects. Since the pathophysiological mechanism
underlying such interaction is as yet unknown, we speculate that
PTGS2 and CYP2E1 genes might interact with each other to play a
role in lung carcinogenesis. Furthermore, considering the diver-
gent genetic profiles, such as the non-mutated rs20417 in our study
population, it is necessary to establish an independent database of
genetic markers for lung cancer in each ethnic group. Moreover,
genotyping data from the PTGS2 and CYP2E1 genes, incorporat-
ing the haplotype and synergism analytical strategy would facilitate
the identification of individuals at high risk of developing lung
cancer in future clinical screening.
Table 3. Haplotype frequencies of the studied
polymorphisms between patients and control, and their risk
prediction for lung cancer after adjusting for confounders.
Haplotype*
Patients
(%)
Controls
(%) PSim OR; 95% CI; P
{
A-T-C-T 37.47 36.61 0.206 Reference group
A-C-T-A 2.0 3.07 0.744 0.8; 0.41–1.56; 0.505
A-T-C-A 4.94 4.01 0.191 1.43; 0.82–2.49; 0.208
A-T-T-A 4.96 3.56 0.193 1.03; 0.71–1.51; 0.86
A-T-T-T 9.92 6.77 0.02 1.49; 1.21–1.79; 0.012
G-C-C-T 9.33 14.38 0.034 0.72; 0.51–0.93; 0.019
G-T-C-A 6.45 5.42 0.869 1.23; 0.71–2.14; 0.459
G-T-T-A 3.58 4.45 0.193 1.01; 0.62–1.66; 0.938
G-T-T-T 6.03 4.71 0.249 1.37; 0.6–3.12; 0.456
Abbreviations: OR, odds ratio; CI, confidence interval; PSim, simulated P.
*Alleles in haplotype were presented in order of polymorphisms rs689466,
rs5275, rs2031920 and rs6413432.
{P was calculated after adjusting for age, gender, smoking and drinking status.
doi:10.1371/journal.pone.0039814.t003
Table 4. MDR analysis summary.
Best combination of each model Cross-validation consistency Testing accuracy P
rs5275 7 0.591 0.064
rs5275, rs689466 10 0.629 0.029
rs5275, rs689466, rs6413432 10 0.661 0.003*
rs5275, rs689466, rs6413432, rs2031920 10 0.646 0.017
*The overall best MDR model.
doi:10.1371/journal.pone.0039814.t004
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Some limitations should be considered when interpreting the
results. First, the cross-sectional design of this study may preclude
comments on causality, and a survival bias could not be excluded.
Second, we only focused on five polymorphisms in PTGS2 and
CYP2E1 genes and did not cover the whole genomic sequences of
the genes, and thus we may under-evaluate the genetic effects of
other genetic markers, Third, data on the circulating PTGS2 and
CYP2E1 levels are unavailable, which makes us incapable of
comparing their levels across genotypes. The immunocytochem-
ical analysis of PTGS2 expression is ongoing to detect any
genotype-phenotype association [27]. Fourth, the sample size of
this study was relatively small such that our findings need to be
validated in a larger population.
To sum up, our findings demonstrated a potentially synergistic
effect between PTGS2 and CYP2E1 genes on the underlying cause
of lung cancer in northeastern Chinese. Moreover, this study
leaves open the question of divergent genetic profiles across
different ethnic groups. This study provides supporting evidence
for further investigation on pathophysiological mechanisms of
PTGS2 and CYP2E1 genes in lung cancer.
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